Actuate Therapeutics' Data From Its Phase 2 Trial Of Elraglusib In Metastatic Pancreatic Cancer Selected For Presentation At 2026 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Benzinga · 2d ago

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3β (GSK-3β), today announced that data from its Phase 2 study evaluating elraglusib in metastatic pancreatic cancer have been selected for an oral presentation at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI Cancers Symposium), with additional data accepted for poster presentation. ASCO GI Cancers Symposium will be held January 8-10, 2026, in San Francisco, CA. The presentations will highlight results from the Company's Phase 2 study evaluating elraglusib in combination with gemcitabine/nab-paclitaxel (GnP), a first-line chemotherapy regimen for metastatic pancreatic cancer.